Product Name: FesSubtide
Product Number: PE-01BHK95
Size: 200 µg      Price:49.00
1 mg      $US97.00
5 mg      213.00
Peptide Name: FesSubtide

Product Use: For assaying the phosphotransferase activity of Fes/Fps protein-tyrosine kinase (UniProt ID P07332).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KKGEDDDYVDVFG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1660.7 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: Fes

Scientific Background: Fes is a protein-tyrosine kinase of the TK group and Fer family. It functions downstream of membrane bound receptors and is involved in the regulation of the actin cytoskeleton, microtubule assembly, cell adhesion, and cell spreading. Additionally, Fes plays a role in the degranulation of mast cells and acts downstream of the FCER1 receptor and the mast/stem cell growth factor receptor Kit. In addition, Fes is involved in the regulation of cell differentiation as well as in the promotion of neurite growth in response to nerve growth factor (NGF) signalling. Known targets of the Fes protein include BCR, HCLS1/HS1, PECAM1, STAT3, and TRIM28. Phosphorylation of Y713 increases phosphotransferase activity and interaction with Fes. Fes has been demonstrated to be an oncoprotein in several human cancer types, potentially due to abnormal activation of the kinase catalytic function. It was originally identified as an oncoprotein from avian retroviral (Fps in Fujinami sarcoma virus) and cat retroviral (Fes in feline sarcoma virus) studies. Interestingly, Fes has also been shown to act as a tumour-suppressor protein in some human cancer types. For example, reduced or absent expression of the Fes protein is observed in colon cancer specimens and the ectopic expression of Fes in colon cancer cell lines results in the suppression of anchorage-independent cell growth, indicating a tumour suppressing role for the Fes protein. In contrast, Fes expression is significantly elevated in prostate cancer specimens and is thought to actively promote cell growth in renal carcinoma cell lines. In animal studies, mice lacking Fes expression displayed deficits in hematopoiesis and had significantly reduced numbers of circulating mature myeloid cells and immature myeloid precursors, indicating a oncogenic role for the Fes protein in this cancer.